Clinical trial

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

NCT04680442

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-07-01

PhasePHASE2

Study timeline

Study start (actual)2021-07-01Date precision: day

Registry last updated2025-04-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Heart Failureunresolved

Interventions

TrastuzumabDRUG · verified · RxNorm: trastuzumab

PertuzumabDRUG · verified · RxNorm: pertuzumab

Trastuzumab emtansineDRUG

Sponsors & collaborators

Population Health Research Institutelead sponsor

Mapped research locations

São PauloSão Paulo, Brazil2 Porto AlegreRio Grande do Sul, Brazil2 TorontoOntario, Canada1 OttawaOntario, Canada1 NovosibirskRussia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04680442 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.